Vesiculin derived from IGF-II drives increased islet cell mass in a mouse model of pre-diabetes.

ABSTRACT: Pancreatic islet-cell function and volume are both key determinants of the maintenance of metabolic health. Insulin resistance and islet-cell dysfunction often occur in the earlier stages of type 2 diabetes (T2D) progression. The ability of the islet cells to respond to insulin resistance by increasing hormone output accompanied by increased islet-cell volume is key to maintaining blood glucose control and preventing further disease progression. Eventual β-cell loss is the main driver of full-blown T2D and insulin-dependency. Researchers are targeting T2D with approaches that include those aimed at enhancing the function of the patient's existing β-cell population, or replacing islet β-cells. Another approach is to look for agents that enhance the natural capacity of the β-cell population

SUBMITTER: Lee KL 

PROVIDER: S-EPMC8632304 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature